menu
    • menu
    [{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"T3D-959","moa":"Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor delta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"T3D Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"National Institute on Aging | Clinilabs | Alzheimer's Association","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"T3D-959","moa":"Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor delta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ National Institute on Aging | Clinilabs | Alzheimer's Association","highestDevelopmentStatusID":"9","companyTruncated":"T3D Therapeutics \/ National Institute on Aging | Clinilabs | Alzheimer's Association"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"T3D-959","moa":"Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor delta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"T3D Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"T3D-959","moa":"Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor delta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"T3D Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"T3D-959","moa":"Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor delta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"T3D Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"T3D-959","moa":"Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor delta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"9","companyTruncated":"T3D Therapeutics \/ Alzheimer\u2019s Association"}]

    Find Clinical Drug Pipeline Developments & Deals by T3D Therapeutics

    Menu

    T3D Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

                            Details : T3D-959 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 09, 2025

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            T3D Therapeutics Announces Positive Top-Line Results from the Phase 2 PIONEER Trial of T3D-959 in Mild-To-Mode...

                            Details : T3D-959, a small molecule, delivered orally once daily, is a brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 03, 2023

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Alzheimer’s Association

                            Deal Size : $0.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership...

                            Details : PIONEER is a double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study enrolling mild-to-moderate Alzheimer's disease patients. The grant will support Phase 2 PIONEER study in mild-to-moderate Alzheimer's disease subjects.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 27, 2020

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Alzheimer’s Association

                            Deal Size : $0.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            T3D Begins Enrollment in PIONEER Phase 2 Trial of T3D-959

                            Details : The Phase 2 PIONEER trial will assess the longitudinal safety, tolerability, clinical efficacy and pharmacodynamics of T3D-959, as well as its effects on biomarkers of neurodegeneration.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 11, 2020

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National Institute on Aging | Clinilabs | Alzheimer's Association

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

                            Details : T3D-959 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2020

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National Institute on Aging | Clinilabs | Alzheimer's Association

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            T3D Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

                            Details : T3D-959 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 25, 2015

                            Lead Product(s) : T3D-959

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth